A 12 week, randomised, double blind parallel group prospective dose ranging study of ZYH1 with an open Rosiglitazone arm to evaluate the efficacy on dyslipidemia in patients with diabetes.

Trial Profile

A 12 week, randomised, double blind parallel group prospective dose ranging study of ZYH1 with an open Rosiglitazone arm to evaluate the efficacy on dyslipidemia in patients with diabetes.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Rosiglitazone; Saroglitazar
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 12 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top